Ocular Therapeutix (OCUL) PT Raised to $11 at Raymond James
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts OCUL Hot Sheet
Price: $7.12 +4.40%
Rating Summary:
21 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
21 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Raymond James analyst Dane Leone raised the price target on Ocular Therapeutix (NASDAQ: OCUL) to $11.00 (from $10.00) while maintaining a Strong Buy rating following FDA approval.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fidelity National Information Services (FIS) PT Lowered to $35 at Raymond James
- Procore Technologies, Inc (PCOR) PT Raised to $68 at Mizuho
- Procore Technologies, Inc (PCOR) PT Raised to $85 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Raymond James, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
